Asthma: Difference between revisions

Page semi-protected
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 209: Line 209:
====Exercise-induced====
====Exercise-induced====
{{Main|Exercise-induced asthma}}
{{Main|Exercise-induced asthma}}
Exercise can trigger brochoconstriction in both people with and without asthma.<ref name=EIB2012>{{cite journal|last=Khan|first=DA|title=Exercise-induced bronchoconstriction: burden and prevalence.|journal=Allergy and asthma proceedings : the official journal of regional and state allergy societies|date=2012 Jan-Feb|volume=33|issue=1|pages=1-6|pmid=22370526}}</ref> It occurs in most people with asthma and up to 20% of people without asthma.<ref name=EIB2012/> In athletes it occurs more common in elite athletes with rates varying from 3% for bobsled racer to 50% for cycling and 60% for cross-country skiing.<ref name=EIB2012/> Beta2-agonists do not appear to improve performance.<ref>{{cite journal|last=Carlsen|first=KH|coauthors=Anderson, SD; Bjermer, L; Bonini, S; Brusasco, V; Canonica, W; Cummiskey, J; Delgado, L; Del Giacco, SR; Drobnic, F; Haahtela, T; Larsson, K; Palange, P; Popov, T; van Cauwenberge, P; European Respiratory, Society; European Academy of Allergy and Clinical, Immunology; GA(2)LEN,|title=Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN.|journal=Allergy|date=2008 May|volume=63|issue=5|pages=492-505|pmid=18394123}}</ref>
Exercise can trigger brochoconstriction in both people with and without asthma.<ref name=EIB2012>{{cite journal|last=Khan|first=DA|title=Exercise-induced bronchoconstriction: burden and prevalence.|journal=Allergy and asthma proceedings : the official journal of regional and state allergy societies|date=2012 Jan-Feb|volume=33|issue=1|pages=1-6|pmid=22370526}}</ref> It occurs in most people with asthma and up to 20% of people without asthma.<ref name=EIB2012/> In athletes it occurs more common in elite athletes with rates varying from 3% for bobsled racer to 50% for cycling and 60% for cross-country skiing.<ref name=EIB2012/> Inhaled beta2-agonists do not appear to improve athletic performance among those without asthma<ref>{{cite journal|last=Carlsen|first=KH|coauthors=Anderson, SD; Bjermer, L; Bonini, S; Brusasco, V; Canonica, W; Cummiskey, J; Delgado, L; Del Giacco, SR; Drobnic, F; Haahtela, T; Larsson, K; Palange, P; Popov, T; van Cauwenberge, P; European Respiratory, Society; European Academy of Allergy and Clinical, Immunology; GA(2)LEN,|title=Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN.|journal=Allergy|date=2008 May|volume=63|issue=5|pages=492-505|pmid=18394123}}</ref> however oral doses may improve endurance and strength.<ref>{{cite journal|last=Kindermann|first=W|title=Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?|journal=Sports medicine (Auckland, N.Z.)|date=2007|volume=37|issue=2|pages=95-102|pmid=17241101}}</ref><ref>{{cite journal|last=Pluim|first=BM|coauthors=de Hon, O; Staal, JB; Limpens, J; Kuipers, H; Overbeek, SE; Zwinderman, AH; Scholten, RJ|title=β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials.|journal=Sports medicine (Auckland, N.Z.)|date=2011 Jan 1|volume=41|issue=1|pages=39-57|pmid=21142283}}</ref>


====Occupational====
====Occupational====

Revision as of 23:32, 24 December 2012

For other uses, see Asthma (disambiguation).

Asthma
SpecialtyPulmonology, immunology Edit this on Wikidata

Asthma (from the Greek ἅσθμα, ásthma, "panting") is the common chronic inflammatory disease of the airways characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm.[1] Symptoms include wheezing, coughing, chest tightness, and shortness of breath.[2] Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate.[3] Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic).[4]

It is thought to be caused by a combination of genetic and environmental factors.[5] Treatment of acute symptoms is usually with an inhaled short-acting beta-2 agonist (such as salbutamol).[6] Symptoms can be prevented by avoiding triggers, such as allergens[7] and irritants, and by inhaling corticosteroids.[8] Leukotriene antagonists are less effective than corticosteroids and thus less preferred.[9]

Its diagnosis is usually made based on the pattern of symptoms and/or response to therapy over time.[10] The prevalence of asthma has increased significantly since the 1970s. As of 2010, 300 million people were affected worldwide. In 2009 asthma caused 250,000 deaths globally.[11]

Signs and symptoms

Wheezing
The sound of wheezing as heard with a stethoscope.
Problems playing this file? See media help.

Asthma is characterized by recurrent episodes of wheezing, shortness of breath, chest tightness and coughing.[12] Symptoms are often worse at night and in the early morning, or in response to exercise or cold air.[13] Some people with asthma only rarely experience symptoms, usually in response to triggers, whereas other may have marked persistent airflow obstruction.s.[14]

Associated conditions

A number of other health conditions occur more frequently in those with asthma including: gastro-esophageal reflux disease (GERD), rhinosinusitis, and obstructive sleep apnea.[15] Psychological disorders are also more common.[16]

Causes

Asthma is caused by environmental and genetic factors.[5] These factors influence how severe asthma is and how well it responds to medication.[17] The interaction is complex and not fully understood.[18] It is believed that the recent increased rates of asthma are due to epigenetic or environmental changes.[19]

Environmental

Many environmental risk factors have been associated with asthma development and exacerbations in children. There is a relationship between exposure to air pollutants (e.g. from traffic) and asthma in children.[20] Maternal tobacco smoking during pregnancy and after delivery is associated with a greater risk of asthma-like symptoms, wheezing, and respiratory infections during childhood.[21] Low air quality, from traffic pollution or high ozonelevels,[22] has been repeatedly associated with increased asthma morbidity and has been association with asthma development.[23] Both the occurrence of the disease and exacerbation of childhood asthma are affected by outdoor air pollutants. High levels of endotoxin exposure may contribute to asthma risk.[24]

Much allergic asthma is associated with sensitivity to indoor allergens and because Western styles of housing favor greater exposure to indoor allergens, much attention has focused on increased exposure to these allergens in infancy and early childhood as a primary cause of the rise in asthma.[25][26] Primary prevention studies aimed at the reduction of airborne allergens in the home have shown mixed findings. Reduction of dust mite allergens, for example, reduces the risk of allergic sensitization to dust mites, and modestly reduces the risk of developing asthma up until the age of 8 years old. However, studies also showed that the effects of exposure to cat and dog allergens worked in the converse fashion; exposure during the first year of life was found to reduce the risk of allergic sensitization and of developing asthma later in life.[27][28][29]

Viral respiratory infections are one of the leading triggers of an exacerbation and may also increase the risk of developing asthma especially in young children.[30][31] Indoor allergens may also play a role with common ones including: dust mites, cockroaches, animal dander and molds.[32]

Psychological stress may worsen asthma symptoms. It is thought that stress modulates the immune system to increase the magnitude of the airway inflammatory response to allergens and irritants.[23][33]

Beta blocker medications such as metoprolol may trigger asthma in those who are susceptible.[34]

Indoor exposure to volatile organic compounds (VOCs) may be one trigger of asthma with formaldehyde exposure being positively associated.[35] Phthalates in PVC is associated with asthma in children and adults.[36][37]

There is a link between asthma and the degree of affluence. This could possibly be due to the 'hygiene factor', whereby lack of childhood exposure to some environmental irritants increases the sensitivity of susceptible people to develop asthma on later exposure.[38] Asthma deaths however are most common in low and middle income countries,.[39] Most likely due to income and geography, the incidence of and treatment quality for asthma varies among different racial groups.[40] The prevalence of "severe persistent" asthma is also greater in low-income communities than those with better access to treatment.[40][41]

Hygiene hypothesis

One theory which attempts to explain the increase in rates of asthma worldwide is the hygiene hypothesis[30] —that the rise in the prevalence of allergies and asthma is a direct and unintended result of reduced exposure to a wide variety of different bacteria and virus types in modern societies, or modern hygienic practices preventing childhood infections.[42]

Children living in less hygienic environments (East Germany vs. West Germany,[43] families with many children,[44] day care environments[45]) tend to have lower incidences of asthma and allergic diseases. This seems to run counter to the logic that viruses are often causative agents in exacerbation of asthma.[46][47][48]Additionally, other studies have shown that viral infections of the lower airway may in some cases induce asthma, as a history of bronchiolitis or croup in early childhood is a predictor of asthma risk in later life.[49] Studies which show that upper respiratory tract infections are protective against asthma risk also tend to show that lower respiratory tract infections conversely tend to increase the risk of asthma.[50]

Antibiotic use early in life has been linked to development of asthma[51] in several examples; it is thought that antibiotics make children who are predisposed to atopic immune responses susceptible to development of asthma because they modify gut flora, and thus the immune system (as described by the hygiene hypothesis).[52] The hygiene hypothesis is a hypothesis about the cause of asthma and other allergic disease, and is supported by epidemiologic data for asthma.[53] All of these things may negatively affect exposure to beneficial bacteria and other immune system modulators that are important during development, and thus may cause an increased risk for asthma and allergy.

Delivery via caesarean sections is associated with an increased risk of asthma.[54] The increased risk has been estimated at between 20-80% and has been attributed to the lack of healthy bacterial colonization which results from passage through the birth canal.[55]

Genetic

Over 100 genes have been associated with asthma in at least one genetic association study.[56] However, such studies must be repeated to ensure the findings are not due to chance. Through the end of 2005, 25 genes had been associated with asthma in six or more separate populations:[56]

Template:Multicol 

 Template:Multicol-break


 Template:Multicol-break


 Template:Multicol-break


 Template:Multicol-break


 Template:Multicol-end

Many of these genes are related to the immune system or to modulating inflammation. However, even among this list of highly replicated genes associated with asthma, the results have not been consistent among all of the populations that have been tested.[56] This indicates that these genes are not associated with asthma under every condition, and that researchers need to do further investigation to figure out the complex interactions that cause asthma. One theory is that asthma is a collection of several diseases, and that genes might have a role in only subsets of asthma.[citation needed] For example, one group of genetic differences (single nucleotide polymorphisms in 17q21) was associated with asthma that develops in childhood.[57]

CD14-endotoxin interaction based on CD14 SNP C-159T[58]
Endotoxin levels CC genotype TT genotype
High exposure Low risk High risk
Low exposure High risk Low risk

Some genetic variants may only cause asthma when they are combined with specific environmental exposures, and otherwise may not be risk factors for asthma.[5] The genetic trait, CD14 single nucleotide polymorphism (SNP) C-159T and exposure to endotoxin (a bacterial product) are a well-replicated example of a gene-environment interaction that is associated with asthma. Endotoxin exposure varies from person to person and can come from several environmental sources, including environmental tobacco smoke, dogs, and farms. Researchers have found that risk for asthma changes based on a person's genotype at CD14 C-159T and level of endotoxin exposure.[58]

Medical conditions

Studying the prevalence of asthma and related diseases such as eczema and hay fever have yielded important clues about some key risk factors.[59] The strongest risk factor for developing asthma is a history of atopic disease;[31] this increases one's risk of hay fever by up to 5 fold and the risk of asthma by 3–4 fold.[60]

There is a strong correlation between obesity and the risk of asthma with both increasing in recent years.[61][62] Several factors associated with obesity may play a role in the pathogenesis of asthma, including decreased respiratory function due to a buildup of adipose tissue (fat) and the fact that adipose tissue leads to a pro-inflammatory state, which has been associated with non-eosinophilic asthma.[63]

Asthma has been associated with Churg–Strauss syndrome, and individuals with immunologically mediated urticaria may also experience systemic symptoms with generalized urticaria, rhino-conjunctivitis, orolaryngeal and gastrointestinal symptoms, and asthma.[64]

Exacerbation

Some individuals will have stable asthma for weeks or months and then suddenly develop an episode of acute asthma. Different asthmatic individuals react differently to various factors.[65] However, most individuals can develop severe exacerbation of asthma from several triggering agents.[65][66]

Home factors that can lead to exacerbation include dust, house mites, animal dander (especially cat and dog hair), cockroach allergens and molds at any given home.[65] Perfumes are a common cause of acute attacks in females and children. Both virus and bacterial infections of the upper respiratory tract infection can worsen asthma.[65]

Pathophysiology

Obstruction of the lumen of the bronchiole by mucoid exudate, goblet cell metaplasia, epithelial basement membrane thickening and severe inflammation of bronchiole in a patient with asthma.

Asthma is the result of chronic inflammation of the airways which subsequently results in increased contractability of the smooth muscles that surround the airway in the lungs.[12] This among other factors leads to narrowing of the airway and the classic symptoms of wheezing.[12]

Diagnosis

Although there is currently not a precise physiologic, immunologic, or histologic test for diagnosing asthma, there is broad consensus that physicians should use spirometry whenever possible to guide the diagnosis and management of asthma.[67][68] The diagnosis is made based on the pattern of symptoms (airways obstruction and hyperresponsiveness) and the response to therapy (partial or complete reversibility) over time.[10]

Classification

Clinical classification of severity[3]
Severity (≥ 12 years of age) [30] Symptom frequency Night time symptoms %FEV1 of predicted FEV1 Variability Frequency of SABA use
Intermittent ≤2 per week ≤2 per month ≥80% <20% ≤2 days per week
Mild persistent >2 per week
but not daily 		3–4 per month ≥80% 20–30% >2 days/week
but not daily
Moderate persistent Daily >1 per week but not nightly 60–80% >30% Daily
Severe persistent Throughout the day Frequent (often 7×/week) <60% >30% Several times per day

Asthma is defined by the Global Initiative for Asthma as "a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or in the early morning. These episodes are usually associated with widespread, but variable airflow obstruction within the lung that is often reversible either spontaneously or with treatment".[12]

Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), andpeak expiratory flow rate.[3] Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic), based on whether symptoms are precipitated by allergens (atopic) or not (non-atopic).[4]

While asthma is classified based on severity, at the moment there is no clear method for classifying different subgroups of asthma beyond this system.[69] Finding ways to identify subgroups that respond well to different types of treatments is a current critical goal of asthma research.[69]

Although asthma is a chronic obstructive condition, it is not considered as a part of chronic obstructive pulmonary disease as this term refers specifically to combinations of disease that are irreversible such as bronchiectasis,chronic bronchitis, and emphysema.[30] Unlike these diseases, the airway obstruction in asthma is usually reversible; however, if left untreated, the chronic inflammation from asthma can lead the lungs to become irreversibly obstructed due to airway remodeling.[70] In contrast to emphysema, asthma affects the bronchi, not the alveoli.[71]

Brittle asthma

Main article: Brittle asthma

Brittle asthma is a kind of asthma distinguishable by recurrent, severe attacks.[72] Type 1 brittle asthma is a disease with wide peak flow variability, despite intense medication. Type 2 brittle asthma is background well-controlled asthma with sudden severe exacerbations.[72]

Asthma attack

An acute asthma exacerbation is commonly referred to as an asthma attack. The classic symptoms are shortness of breath, wheezing, and chest tightness.[73] While these are the primary symptoms of asthma,[74] some people present primarily with coughing, and in severe cases, air motion may be significantly impaired such that no wheezing is heard.[72]

Signs which occur during an asthma attack include the use of accessory muscles of respiration (sternocleidomastoid and scalene musclesof the neck), there may be a paradoxical pulse (a pulse that is weaker during inhalation and stronger during exhalation), and over-inflation of the chest.[75] A blue color of the skin and nails may occur from lack of oxygen.[76]

In a mild exacerbation the peak expiratory flow rate (PEFR) is ≥200 L/min or ≥50% of the predicted best.[77] Moderate is defined as between 80 and 200 L/min or 25% and 50% of the predicted best while severe is defined as ≤ 80 L/min or ≤25% of the predicted best.[77]

Status asthmaticus

Main article: Status asthmaticus

Status asthmaticus is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators and steroids. Nonselective beta blockers (such as Timolol) have caused fatal status asthmaticus.[78]

Exercise-induced

Main article: Exercise-induced asthma

Exercise can trigger brochoconstriction in both people with and without asthma.[79] It occurs in most people with asthma and up to 20% of people without asthma.[79] In athletes it occurs more common in elite athletes with rates varying from 3% for bobsled racer to 50% for cycling and 60% for cross-country skiing.[79] Inhaled beta2-agonists do not appear to improve athletic performance among those without asthma[80] however oral doses may improve endurance and strength.[81][82]

Occupational

Main article: Occupational asthma

Asthma as a result of (or worsened by) workplace exposures is a commonly reported occupational respiratory disease. Still most cases of occupational asthma are not reported or are not recognized as such. Estimates by the American Thoracic Society (2004) suggest that 15–23% of new-onset asthma cases in adults are work related.[83] In one study monitoring workplace asthma by occupation, the highest percentage of cases occurred among operators, fabricators, and laborers (32.9%), followed by managerial and professional specialists (20.2%), and in technical, sales, and administrative support jobs (19.2%). Most cases were associated with the manufacturing (41.4%) and services(34.2%) industries.[83] Animal proteins, enzymes, flour, natural rubber latex, and certain reactive chemicals are commonly associated with work-related asthma. When recognized, these hazards can be mitigated, dropping the risk of disease.[84]

Response to therapy

The British Thoracic Society determines a diagnosis of asthma using a ‘response to therapy’ approach. If the patient responds to treatment, then this is considered to be a confirmation of the diagnosis of asthma. The response measured is the reversibility of airway obstruction after treatment. Airflow in the airways is measured with a peak flow meter or spirometer, and the following diagnostic criteria are used by the British Thoracic Society:[85]

  • ≥20% difference on at least three days in a week for at least two weeks;
  • ≥20% improvement of peak flow following treatment, for example:
  • ≥20% decrease in peak flow following exposure to a trigger (e.g., exercise).

By symptom patterns

Severity of acute asthma exacerbations[72]
Near-fatal asthma High PaCO2 and/or requiring mechanical ventilation
Life threatening Any one of the following in a person with severe asthma:-
Clinical signs Measurements
Altered level of consciousness Peak flow < 33%
Exhaustion Oxygen saturation < 92%
Arrhythmia PaO2 < 8 kPa
Low blood pressure "Normal" PaCO2
Cyanosis
Silent chest
Poor respiratory effort
Acute severe Any one of:-
Peak flow 33–50%
Respiratory rate ≥ 25 breaths per minute
Heart rate ≥ 110 beats per minute
Unable to complete sentences in one breath
Moderate Worsening symptoms
Peak flow 50–80% best or predicted
No features of acute severe asthma

In contrast, the US National Asthma Education and Prevention Program (NAEPP) uses a "symptom patterns" approach.[86] Their guidelines for the diagnosis and management of asthma state that a diagnosis of asthma begins by assessing if any of the following list of indicators is present.[87][86] While the indicators are not sufficient to support a diagnosis of asthma, the presence of multiple key indicators increases the probability of a diagnosis of asthma.[86] Spirometry is needed to establish a diagnosis of asthma.[86]

  • Wheezing—high-pitched whistling sounds when breathing out—especially in children. (Lack of wheezing and a normal chest examination do not exclude asthma.)
  • history of any of the following:
    • Cough, worse particularly at night
    • Recurrent wheeze
    • Recurrent difficulty in breathing
    • Recurrent chest tightness
  • Symptoms occur or worsen in the presence of:
    • Exercise
    • Viral infection
    • Animals with fur or hair
    • House-dust mites (in mattresses, pillows, upholstered furniture, carpets)
    • Mold
    • Smoke (tobacco, wood)
    • Pollen
    • Changes in weather
    • Strong emotional expression (laughing or crying hard)
    • Airborne chemicals or dusts
    • Menstrual cycles
  • Symptoms occur or worsen at night, awakening the patient

The latest guidelines from the U.S. National Asthma Education and Prevention Program (NAEPP) recommend spirometry at the time of initial diagnosis, after treatment is initiated and symptoms are stabilized, whenever control of symptoms deteriorates, and every 1 or 2 years on a regular basis.[88] The NAEPP guidelines do not recommend testing peak expiratory flow as a regular screening method because it is more variable than spirometry. However, testing peak flow at rest (or baseline) and after exercise can be helpful, especially in young patients who may experience only exercise-induced asthma. It may also be useful for daily self-monitoring and for checking the effects of new medications.[88] Peak flow readings can be charted together with a record of symptoms or use peak flow charting software. This allows patients to track their peak flow readings and pass information back to their doctor or respiratory therapist.[89]

Differential diagnosis

Other conditions may cause symptoms similar to those of asthma and a physician would conduct differential diagnoses to determine if any of the following could be causes of symptoms:[86]

Before diagnosing asthma, alternative possibilities should be considered such as the use of known bronchoconstrictors (substances that cause narrowing of the airways, e.g. certain anti-inflammatory agents or beta-blockers). Among elderly people, the presenting symptom may be fatigue, cough, or difficulty breathing, all of which may be erroneously attributed to Chronic obstructive pulmonary disease(COPD), congestive heart failure, or simple aging.[90]

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease can coexist with asthma and can occur as a complication of chronic asthma. After the age of 65 most people with obstructive airway disease will have asthma and COPD. In this setting, COPD can be differentiated by increased airway neutrophils, abnormally increased wall thickness, and increased smooth muscle in the bronchi. However, this level of investigation is not performed due to COPD and asthma sharing similar principles of management: corticosteroids, long acting beta agonists, and smoking cessation.[91] It closely resembles asthma in symptoms, is correlated with more exposure to cigarette smoke, an older age, less symptom reversibility after bronchodilator administration (as measured by spirometry), and decreased likelihood of family history of atopy.[92][93]

Others

This triad of atopic eczema, allergic rhinitis, and asthma is called atopy.[64]

Pulmonary aspiration, whether direct due to dysphagia (swallowing disorder) or indirect (due to acid reflux), can show similar symptoms to asthma. However, with aspiration, fevers might also indicate aspiration pneumonia. Direct aspiration (dysphagia) can be diagnosed by performing a modified barium swallow test. If the aspiration is indirect (from acid reflux), then treatment is directed at this is indicated.[citation needed]

Prevention

The evidence for the effectiveness of measures to prevent the development of asthma is weak.[94] Ones which show some promise include limiting smoke exposure both in utero and after delivery, breastfeeding, increased exposure to respiratory infection per the hygiene hypothesis (such as in those who attend daycare or are from large families).[94]

Management

While there is no cure for asthma, symptoms can typically be improved.[95] A specific, customized plan for proactively monitoring and managing symptoms should be created. This plan should include the reduction of exposure to allergens, testing to assess the severity of symptoms, and the usage of medications. The treatment plan should be written down and adjusted according to changes in symptoms.[96]

The most effective treatment for asthma is identifying triggers, such as cigarette smoke, pets, or aspirin, and eliminating exposure to them. If trigger avoidance is insufficient, the use of medication is recommended. Pharmaceutical drugs are selected based on, among other things, the severity of illness and the frequency of symptoms. Specific medications for asthma are broadly classified into fast-acting and long-acting categories.[97][98]

Bronchodilators are recommended for short-term relief of symptoms. In those with occasional attacks, no other medication is needed. If mild persistent disease is present (more than two attacks a week), low-dose inhaled glucocorticoids or alternatively, an oral leukotriene antagonist or a mast cell stabilizer is recommended. For those who have daily attacks, a higher dose of inhaled glucocorticoid is used. In a severe asthma exacerbation, oral glucocorticoids are added to these treatments.[86]

Lifestyle modification

Avoidance of triggers is a key component of improving control and preventing attacks. The most common triggers include allergens, smoke (tobacco and other), air pollution, non selective beta-blockers, and sulfite-containing foods.[86][99][100][101] Cigarette smoking and second-hand smoke (passive smoke) may reduce the effectiveness of management medications such as steroid therapies.[102] Dust mite control measures, including air filtration, chemicals to kill mites, vacuuming, mattress covers and others methods had no effect on asthma symptoms.[103]

Medications

Medications used to treat asthma are divided into two general classes: quick-relief medications used to treat acute symptoms; and long-term control medications used to prevent further exacerbation.[97]

Fast acting
Salbutamol metered dose inhaler commonly used to treat asthma attacks.
Long term control
Fluticasone propionate metered dose inhaler commonly used for long term control.
  • Glucocorticoids are generally considered the most effective treatment available for long term control.[97] Inhaled forms are usually used except in the case of severe persistent disease, in which oral steroids may be needed.[97] It is usually recommended that inhaled formulations be used once or twice daily, depending on the severity of symptoms.[106]
Delivery methods

Medications are typically provided as metered-dose inhalers (MDIs) in combination with an asthma spacer or as a dry powder inhaler. The spacer is a plastic cylinder that mixes the medication with air, making it easier to receive a full dose of the drug. A nebulizer may also be used. Nebulizers and spacers are equally effective in those with mild to moderate symptoms however insufficient evidence is available to determine whether or not a difference exists in those severe symptomatology.[110]

Adverse effects

Long-term use of inhaled glucocorticoids at conventional doses carries a minor risk of adverse effects.[111] Risks include the development of cataracts and a mild regression in stature.[111][112]

Other

When asthma is unresponsive to usual medications, other options are available for both emergency management and prevention of flareups. For emergency management other options include:

  • Oxygen is used to alleviate hypoxia if saturations fall below 92%.[113]
  • Magnesium sulfate intravenous treatment has been shown to provide a bronchodilating effect when used in addition to other treatment in severe acute asthma attacks.[114][115]
  • Heliox, a mixture of helium and oxygen, may also be considered in severe unresponsive cases.[115]
  • Intravenous salbutamol is not supported by available evidence and is thus used only in extreme cases.[113]
  • Methylxanthines (such as theophylline) were once widely used, but do not add significantly to the effects of inhaled beta-agonists.[113]
  • The dissociative anesthetic ketamine is theoretically useful if intubation and mechanical ventilation is needed in people who are approaching respiratory arrest; however, there is no evidence from clinical trials to support this.[116]

For those with severe persistent asthma not controlled by inhaled corticosteroids and LABAs bronchial thermoplasty can lead to clinical improvements.[117] It involves the delivery of controlled thermal energy to the airway wall during a series of bronchoscopies and result in a prolonged reduction in airway smooth muscle mass.[117]

Alternative medicine

Many people with asthma, like those with other chronic disorders, use alternative treatments; surveys show that roughly 50% use some form of unconventional therapy.[118][119] There is little data to support the effectiveness of most of these therapies. Evidence is insufficient to support the usage of Vitamin C.[120] Acupuncture is not recommended for the treatment as there is insufficient evidence to support its use.[121][122] Air ionisers show no evidence that they improve asthma symptoms or benefit lung function; this applied equally to positive and negative ion generators.[123]

"Manual therapies", including osteopathic, chiropractic, physiotherapeutic and respiratory therapeutic maneuvers, have insufficient evidence to support their use in treating asthma.[124] The Buteyko breathing technique for controlling hyperventilation may result in a reduction in medications use however does not have any effect on lung function.[98] Thus an expert panel felt that evidence was insufficient to support its use.[121]

Prognosis

The prognosis for asthma is generally good, especially for children with mild disease.[125] Of asthma diagnosed during childhood, 54% of cases will no longer carry the diagnosis after a decade.[citation needed] The extent of permanent lung damage in people with asthma is unclear. Airway remodeling is observed, but it is unknown whether these represent harmful or beneficial changes.[126] Although conclusions from studies are mixed, most studies show that early treatment with glucocorticoids prevents or ameliorates decline in lung function as measured by several parameters.[127] For those who continue to suffer from mild symptoms, corticosteroids can help most to live their lives with few disabilities. It is more likely to consider immediate medication of inhaled corticosteroids as soon as asthma attacks occur. According to studies conducted, patients with relatively mild asthma who have received inhaled corticosteroids within 12 months of their first asthma symptoms achieved good functional control of asthma after 10 years of individualized therapy as compared to patients who received this medication after 2 years (or more) from their first attacks.[citation needed] Though they (delayed) also had good functional control of asthma, they were observed to exhibit slightly less optimal disease control and more signs of airway inflammation.[citation needed]

Asthma mortality has decreased over the last few decades due to better recognition and improvement in care.[128] Globally it causes moderate or severe disability in 19.4 million people as of 2004 (16 million of which are in low and middle income countries).[129]

Epidemiology

Disability-adjusted life year for asthma per 100,000 inhabitants in 2004.[130] Template:Multicol
  no data
  <100
  100–150
  150–200
  200–250
  250–300
  300–350
Template:Multicol-break
  350–400
  400–450
  450–500
  500–550
  550–600
  >600
Template:Multicol-end

As of 2009, ~300 million people worldwide (7-10% of the population) were affected by asthma.[131][132] Approximately 180,000 people die per year from the disease.[133]

Rates vary across the world, with a trend toward more developed countries being more affected with as much as a 20 to 60-fold difference.[134] Westernization does not explain the entire difference in asthma prevalence between countries, and the disparities may also be affected by differences in genetic, social and environmental risk factors.[23] Mortality from asthma is most common in low to middle income countries,[135] while symptoms were most prevalent (as much as 20%) in the United Kingdom, Australia, New Zealand, and Republic of Ireland; they were lowest (as low as 2–3%) in Eastern Europe, Indonesia, Greece, Uzbekistan, India, and Ethiopia.[134]

Asthma affects approximately 7% of the population of the United States[9] and 5% of people in the United Kingdom.[136] Asthma causes 4,210 deaths per year in the United States.[132][137] In 2005 in the United States asthma affected more than 22 million people including 6 million children.[128] It accounted for nearly 1/2 million hospitalizations that same year.[128] More boys have asthma than girls, but more women have it than men.[138] In England, an estimated 261,400 people were newly diagnosed with asthma in 2005; 5.7 million people had an asthma diagnosis and were prescribed 32.6 million asthma-related prescriptions.[139]

Increasing frequency

The prevalence of childhood asthma in the United States has increased since 1980, especially in younger children.

Rates of asthma have increased significantly between the 1960s and 2008[140][141] with it being recognized as a major public health problem in the 1970s.[142] Some 9% of US children had asthma in 2001, compared with just 3.6% in 1980. The World Health Organization (WHO) reports that some 10% of the Swiss population have asthma as of 2007, compared with 2% some 25–30 years ago.[143] In the United States the age-adjusted prevalence of asthma increased from 7.3 to 8.2 percent during the years 2001 through 2009 .[144] Previous analysis of data from 2001 to 2007 had suggested the prevalence of asthma was stable.[144]

Variability

Asthma prevalence in the US is higher than in most other countries in the world, but varies drastically between diverse US populations.[23] In the US, asthma prevalence is highest in Puerto Ricans, African Americans, Filipinos, Irish Americans, and Native Hawaiians, and lowest in Mexicans and Koreans.[145][146][147] Mortality rates follow similar trends, and response to salbutamol is lower in Puerto Ricans than in African Americans or Mexicans.[148][149] As with worldwide asthma disparities, differences in asthma prevalence, mortality, and drug response in the US may be explained by differences in genetic, social and environmental risk factors.

Asthma prevalence also differs between populations of the same ethnicity who are born and live in different places.[150] US-born Mexican populations, for example, have higher asthma rates than non-US born Mexican populations that are living in the US.[151]

There is no correlation between asthma and gender in children. More adult women are diagnosed with asthma than adult men, but this does not necessarily mean that more adult women have asthma.[152]

History

Asthma was recognized in Ancient Egypt and was treated by drinking an incense mixture known as kyphi[153] Officially recognized as a specific respiratory problem separate from others was first recognized and named by Hippocrates circa 450 BC. During the 1930s–50s, asthma was considered as being one of the 'holy seven' psychosomatic illnesses. Its aetiology was considered to be psychological, with treatment often based on psychoanalysis and other 'talking cures'.[154] As these psychoanalysts interpreted the asthmatic wheeze as the suppressed cry of the child for its mother, they considered that the treatment of depression was especially important for individuals with asthma.[154] Among the first papers in modern medicine published on the subject are one published in 1873, which tried to explain the pathophysiology of the disease [155] and one in 1872, which concluded that asthma can be cured by rubbing the chest with chloroform liniment.[156]

Some of the first references to medical treatment include one in 1880, when Dr. J. B. Berkart used IV therapy to administer doses of a drug called pilocarpin.[157] In 1886, F.H. Bosworth theorized a connection between asthma and hay fever.[158] Epinephrine was first referred to in the treatment of asthma in 1905,[159] and again for acute asthma in 1910.[160]

Notes

  1. ^ NHLBI Guideline 2007, pp. 11–12
  2. ^ British Guideline 2009, p. 3
  3. ^ a b c Yawn, BP (2008). "Factors accounting for asthma variability: achieving optimal symptom control for individual patients" (PDF). Primary Care Respiratory Journal. 17 (3): 138–147. doi:10.3132/pcrj.2008.00004. PMID 18264646. {{cite journal}}: Unknown parameter |month= ignored (help)
  4. ^ a b Kumar, Vinay; Abbas, Abul K; Fausto, Nelson; Aster, Jon (2010). Robbins and Cotran Pathologic Basis of Disease (8th ed.). Saunders. p. 688. ISBN 978-1-4160-3121-5.
  5. ^ a b c Martinez FD (2007). "Genes, environments, development and asthma: a reappraisal". Eur Respir J. 29 (1): 179–84. doi:10.1183/09031936.00087906. PMID 17197483.
  6. ^ a b c NHLBI Guideline 2007, p. 214
  7. ^ NHLBI Guideline 2007, pp. 169–172
  8. ^ GINA 2011, p. 71
  9. ^ a b c Fanta CH (2009). "Asthma". New England Journal of Medicine. 360 (10): 1002–14. doi:10.1056/NEJMra0804579. PMID 19264689. {{cite journal}}: Unknown parameter |month= ignored (help)
  10. ^ a b Lemanske RF, Busse WW (2010). "Asthma: clinical expression and molecular mechanisms". J. Allergy Clin. Immunol. 125 (2 Suppl 2): S95–102. doi:10.1016/j.jaci.2009.10.047. PMC 2853245. PMID 20176271. {{cite journal}}: Unknown parameter |month= ignored (help)
  11. ^ GINA 2011, p. 3
  12. ^ a b c d GINA 2011, pp. 2
  13. ^ British Guideline 2009, p. 12
  14. ^ GINA 2011, p. 8-9
  15. ^ Boulet LP (2009). "Influence of comorbid conditions on asthma". Eur Respir J. 33 (4): 897–906. doi:10.1183/09031936.00121308. PMID 19336592. {{cite journal}}: Unknown parameter |month= ignored (help)
  16. ^ Boulet, LP (2011 Jun). "Asthma-related comorbidities". Expert review of respiratory medicine. 5 (3): 377–93. PMID 21702660. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  17. ^ Choudhry S, Seibold MA, Borrell LN; et al. (2007). "Dissecting complex diseases in complex populations: asthma in latino americans". Proc Am Thorac Soc. 4 (3): 226–33. doi:10.1513/pats.200701-029AW. PMC 2647623. PMID 17607004. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  18. ^ Miller, RL (2008). "Environmental epigenetics and asthma: current concepts and call for studies". American Journal of Respiratory and Critical Care Medicine. 177 (6): 567–573. doi:10.1164/rccm.200710-1511PP. PMC 2267336. PMID 18187692. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  19. ^ Dietert, RR (2011 Sep). "Maternal and childhood asthma: risk factors, interactions, and ramifications". Reproductive toxicology (Elmsford, N.Y.). 32 (2): 198–204. PMID 21575714. {{cite journal}}: Check date values in: |date= (help)
  20. ^ Salam MT, Islam T, Gilliland FD (January 2008). "Recent evidence for adverse effects of residential proximity to traffic sources on asthma". Curr Opin Pulm Med. 14 (1): 3–8. doi:10.1097/MCP.0b013e3282f1987a. PMID 18043269.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  21. ^ GINA 2011, p. 6
  22. ^ GINA 2011, p. 61
  23. ^ a b c d Gold DR, Wright R (2005). "Population disparities in asthma". Annu Rev Public Health. 26: 89–113. doi:10.1146/annurev.publhealth.26.021304.144528. PMID 15760282.
  24. ^ Liu AH (2004). "Something old, something new: indoor endotoxin, allergens and asthma". Paediatr Respir Rev. 5 (Suppl A): S65–71. doi:10.1016/S1526-0542(04)90013-9. PMID 14980246.
  25. ^ Peat JK, Tovey E, Toelle BG; et al. (1996). "House dust mite allergens: A major risk factor for childhood asthma in Australia". Am J Respir Crit Care Med. 153 (1): 141–6. PMID 8542107. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  26. ^ Custovic A, Smith AC, Woodcock A (1998). "Indoor allergens are a primary cause of asthma: Asthma and the environment". Eur Respir Rev. 53: 155–8.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. ^ Celedon JC, Litonjua AA, Ryan L; et al. (2002). "Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life". Lancet. 360 (9335): 781–2. doi:10.1016/S0140-6736(02)09906-3. PMID 12241839. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  28. ^ Ownby DR, Johnson CC, Peterson EL (2002). "Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age". JAMA. 288 (8): 963–972. doi:10.1001/jama.288.8.963. PMID 12190366.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. ^ Perzanowski MS, Ronmark E, Platts-Mills TA, Lundback B (2002). "Effect of cat and dog ownership on sensitization and development of asthma among preteenage children". Am J Respir Crit Care Med. 166 (5): 696–702. doi:10.1164/rccm.2201035. PMID 12204868.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. ^ a b c d e Self, Timothy. Chrisman,Cary. Finch, Christopher. "Applied Therapeutics: The Clinical Use of Drugs, 9th Edition" Philadelphia: Lippincott Williams & Wilkins, 2009. Chapter 22 (Asthma)
  31. ^ a b NHLBI Guideline 2007, p. 11
  32. ^ Arshad, SH (2010 Jan). "Does exposure to indoor allergens contribute to the development of asthma and allergy?". Current allergy and asthma reports. 10 (1): 49–55. PMID 20425514. {{cite journal}}: Check date values in: |date= (help)
  33. ^ Chen E, Miller GE (2007). "Stress and inflammation in exacerbations of asthma". Brain Behav Immun. 21 (8): 993–9. doi:10.1016/j.bbi.2007.03.009. PMC 2077080. PMID 17493786.
  34. ^ O'Rourke ST (2007). "Antianginal actions of beta-adrenoceptor antagonists". Am J Pharm Educ. 71 (5): 95. PMC 2064893. PMID 17998992. {{cite journal}}: Unknown parameter |month= ignored (help)
  35. ^ McGwin, G (2010 Mar). "Formaldehyde exposure and asthma in children: a systematic review". Environmental health perspectives. 118 (3): 313–7. PMID 20064771. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  36. ^ Jaakkola JJ, Knight TL. (2008). "The role of exposure to phthalates from polyvinyl chloride products in the development of asthma and allergies: a systematic review and meta-analysis". Environ Health Perspect. 116 (7): 845–53. doi:10.1289/ehp.10846. PMC 2453150. PMID 18629304. {{cite journal}}: Unknown parameter |month= ignored (help)
  37. ^ Bornehag, CG (2010 Apr). "Phthalate exposure and asthma in children". International journal of andrology. 33 (2): 333–45. PMID 20059582. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  38. ^ Von Hertzen, LC (2004 Feb). "Asthma and atopy -the price of affluence?". Allergy. 59 (2): 124–37. PMID 14763924. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  39. ^ "WHO | Asthma". Who.int. 2008-06-03. Archived from the original on 8 March 2010. Retrieved 2010-04-16. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  40. ^ a b National Center for Health Statistics (7 April 2006). "Asthma Prevalence, Health Care Use and Mortality, 2002". Centers for Disease Control and Prevention.
  41. ^ National Heart, Lung, and Blood Institute (2004). "Morbidity & Mortality: 2004 Chart Book On Cardiovascular, Lung, and Blood Diseases". National Institutes of Health. {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  42. ^ Ramsey, CD (2005). "The hygiene hypothesis and asthma". Current Opinion in Pulmonary Medicine. 11 (1): 14–20. doi:10.1097/01.mcp.0000145791.13714.ae. PMID 15591883. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  43. ^ de Lara, C (2007). "Dishing the dirt on asthma: What we can learn from poor hygiene". Biologics. 1 (2): 139–150. PMC 2721305. PMID 19707324. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  44. ^ Strachan DP (1989). "Hay fever, hygiene, and household size". BMJ. 299 (6710): 1259–60. doi:10.1136/bmj.299.6710.1259. PMC 1838109. PMID 2513902.
  45. ^ Ball TM, Castro-Rodriguez JA, Griffith KA; et al. (2000). "Siblings, day-care attendance, and the risk of asthma and wheezing during childhood". N Engl J Med. 343 (8): 538–543. doi:10.1056/NEJM200008243430803. PMID 10954761. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  46. ^ Pattemore PK, Johnston SL, Bardin PG (1992). "Viruses as precipitants of asthma symptoms. I Epidemiology". Clin Exp Allergy. 22 (3): 325–336. doi:10.1111/j.1365-2222.1992.tb03094.x. PMID 1586873.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  47. ^ Nicholson KG, Kent J, Ireland DC (1993). "Respiratory viruses and exacerbations of asthma in adults". BMJ. 307 (6910): 982–996. PMC 1679193. PMID 8241910.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  48. ^ Tan WC, Xiang X, Qiu D; et al. (2003). "Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease". Am J Med. 115 (4): 272–7. doi:10.1016/S0002-9343(03)00353-X. PMID 12967691. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  49. ^ Weiss ST, Tager IB, Munoz A, Speizer FE (1985). "The relationship of respiratory infections in early childhood to the occurrence of increased levels of bronchial responsiveness and atopy". Am Rev Respir Dis. 131 (4): 573–8. PMID 3994151.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  50. ^ Illi S, von Mutius E, Lau S; et al. (2001). "Early childhood infectious diseases and the development of asthma up to school age: A birth cohort study". BMJ. 322 (7283): 390–5. doi:10.1136/bmj.322.7283.390. PMC 26566. PMID 11179155. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  51. ^ Murk, W (2011 Jun). "Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review". Pediatrics. 127 (6): 1125–38. doi:10.1542/peds.2010-2092. PMID 21606151. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  52. ^ Droste, JH (2000). "Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease?". Clinical and Experimental Allergy. 30 (11): 1547–1553. PMID 11069562. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  53. ^ Bufford, JD (2005). "The hygiene hypothesis revisited". Immunology and Allergy Clinics of North America. 25 (2): 247–262. doi:10.1016/j.iac.2005.03.005. PMID 15878454. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  54. ^ British Guideline 2009, p. 72
  55. ^ Neu, J (2011 Jun). "Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis". Clinics in perinatology. 38 (2): 321–31. PMID 21645799. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  56. ^ a b c Ober C, Hoffjan S (2006). "Asthma genetics 2006: the long and winding road to gene discovery". Genes Immun. 7 (2): 95–100. doi:10.1038/sj.gene.6364284. PMID 16395390.
  57. ^ Bouzigon E, Corda E, Aschard H; et al. (2008). "Effect of 17q21 Variants and Smoking Exposure in Early-Onset Asthma". The New England Journal of Medicine. 359 (19): 1985. doi:10.1056/NEJMoa0806604. PMID 18923164. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  58. ^ a b Martinez FD (2007). "CD14, endotoxin, and asthma risk: actions and interactions". Proc Am Thorac Soc. 4 (3): 221–5. doi:10.1513/pats.200702-035AW. PMC 2647622. PMID 17607003.
  59. ^ GINA 2011, p. 4
  60. ^ Ronmark E, Lundback B, Jonsson EA; et al. (1997). "Incidence of asthma in adults: Report from the obstructive lung disease in northern Sweden study". Allergy. 52 (11): 1071–81. doi:10.1111/j.1398-9995.1997.tb00178.x. PMID 9404558. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  61. ^ Beuther DA (2010). "Recent insight into obesity and asthma". Curr Opin Pulm Med. 16 (1): 64–70. doi:10.1097/MCP.0b013e3283338fa7. PMID 19844182. {{cite journal}}: Unknown parameter |month= ignored (help)
  62. ^ Holguin F, Fitzpatrick A (2010). "Obesity, asthma, and oxidative stress". J. Appl. Physiol. 108 (3): 754–9. doi:10.1152/japplphysiol.00702.2009. PMID 19926826. {{cite journal}}: Unknown parameter |month= ignored (help)
  63. ^ Wood LG, Gibson PG (2009). "Dietary factors lead to innate immune activation in asthma". Pharmacol. Ther. 123 (1): 37–53. doi:10.1016/j.pharmthera.2009.03.015. PMID 19375453. {{cite journal}}: Unknown parameter |month= ignored (help)
  64. ^ a b Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.{{cite book}}: CS1 maint: multiple names: authors list (link)
  65. ^ a b c d Baxi SN, Phipatanakul W (2010). "The role of allergen exposure and avoidance in asthma". Adolesc Med State Art Rev. 21 (1): 57–71, viii–ix. PMC 2975603. PMID 20568555. {{cite journal}}: Unknown parameter |month= ignored (help)
  66. ^ Asthma definition Mayo Clinic. Retrieved on 2010-02-08
  67. ^ American Academy of Allergy, Asthma, and Immunology, "Five Things Physicians and Patients Should Question" (PDF), Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Allergy, Asthma, and Immunology, retrieved August 14 2012 {{citation}}: Check date values in: |accessdate= (help)CS1 maint: multiple names: authors list (link)
  68. ^ Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (PDF) (NIH Publication Number 08-5846 ed.). National Institutes of Health. 2007.
  69. ^ a b Moore WC, Pascual RM (2010). "Update in asthma 2009". American Journal of Respiratory and Critical Care Medicine. 181 (11): 1181–7. doi:10.1164/rccm.201003-0321UP. PMID 20516492. {{cite journal}}: Unknown parameter |month= ignored (help)
  70. ^ Delacourt, C (2004). "Bronchial changes in untreated asthma". Archives de Pédiatrie. 11 (Suppl. 2): 71s–73s. PMID 15301800. {{cite journal}}: Unknown parameter |month= ignored (help)
  71. ^ Schiffman, George (18 December 2009). "Chronic Obstructive Pulmonary Disease". MedicineNet. Archived from the original on 28 August 2010. Retrieved 2 September 2010. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  72. ^ a b c d British Guideline 2009, p. 54
  73. ^ Mason, Robert J; Broaddus, V Courtney; Murray, John F; Nadel, Jay A (2005). "Asthma". Murray and Nadel's Textbook of Respiratory Medicine (4th ed.). Elsevier. ISBN 978-0-7216-0327-8.
  74. ^ Barnes, PJ (2008). "Asthma". In Fauci, Anthony S; Braunwald, E,; Kasper, DL (eds.). Harrison's Principles of Internal Medicine (17th ed.). New York: McGraw-Hill. pp. 1596–1607. ISBN 978-0-07-146633-2.{{cite book}}: CS1 maint: extra punctuation (link) CS1 maint: multiple names: editors list (link)
  75. ^ Maitre B, Similowski T, Derenne JP (1995). "Physical examination of the adult patient with respiratory diseases: inspection and palpation". Eur. Respir. J. 8 (9): 1584–93. PMID 8575588. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  76. ^ Werner, HA (2001). "Status asthmaticus in children: a review". Chest. 119 (6): 1596–1607. doi:10.1378/chest.119.6.1913. PMID 11399724. {{cite journal}}: Unknown parameter |month= ignored (help)
  77. ^ a b Shiber JR, Santana J (2006). "Dyspnea". Med. Clin. North Am. 90 (3): 453–79. doi:10.1016/j.mcna.2005.11.006. PMID 16473100. {{cite journal}}: Unknown parameter |month= ignored (help)
  78. ^ Dipiro J.T. Talbert R.L. Yee G.C. Matzke G.R. Wells B.G. Posey L.M., (2008). Pharmacotherpay. a pathophysiologic approach (7 ed.). p. 524. {{cite book}}: Unknown parameter |state= ignored (help); Unknown parameter |unused_data= ignored (help)CS1 maint: extra punctuation (link)
  79. ^ a b c Khan, DA (2012 Jan-Feb). "Exercise-induced bronchoconstriction: burden and prevalence". Allergy and asthma proceedings : the official journal of regional and state allergy societies. 33 (1): 1–6. PMID 22370526. {{cite journal}}: Check date values in: |date= (help)
  80. ^ Carlsen, KH (2008 May). "Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN". Allergy. 63 (5): 492–505. PMID 18394123. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: extra punctuation (link)
  81. ^ Kindermann, W (2007). "Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?". Sports medicine (Auckland, N.Z.). 37 (2): 95–102. PMID 17241101.
  82. ^ Pluim, BM (2011 Jan 1). "β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials". Sports medicine (Auckland, N.Z.). 41 (1): 39–57. PMID 21142283. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  83. ^ a b "Fatal and Nonfatal Injuries, and Selected Illnesses and Conditions: Respiratory Diseases". Worker Health Chartbook 2004. National Institute for Occupational Safety and Health. September 2004. Archived from the original on 1 January 2009. Retrieved December 17, 2008. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  84. ^ "Asthma and Allergies". National Institute for Occupational Safety and Health. September 22, 2008. Archived from the original on 29 March 2009. Retrieved March 23, 2009. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  85. ^ Pinnock H, Shah R (2007). "Asthma". BMJ. 334 (7598): 847–50. doi:10.1136/bmj.39140.634896.BE. PMC 1853223. PMID 17446617.
  86. ^ a b c d e f g NHLBI Guideline 2007
  87. ^ Tippets B, Guilbert TW (2009). "Managing Asthma in Children: Part 1: Making the Diagnosis, Assessing Severity". Consultant for Pediatricians. 8 (5).
  88. ^ a b Sapp J, Niven AS (April 7, 2008). "Making the most of pulmonary function testing in the diagnosis of asthma". Journal of Respiratory Diseases. 29 (4). UBM Medica.
  89. ^ "'Be in control' pack". Asthma UK. Archived from the original (PDF) on 6 October 2007. Retrieved 2007-11-19. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  90. ^ deShazo RD, Stupko JE (October 1, 2008). "Diagnosing asthma in seniors: An algorithmic approach". Journal of Respiratory Diseases. 29 (10). UBM Medica.
  91. ^ Gibson PG, McDonald VM, Marks GB (2010). "Asthma in older adults". Lancet. 376 (9743): 803–13. doi:10.1016/S0140-6736(10)61087-2. PMID 20816547. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  92. ^ Hargreave, FE (2006). "Asthma, COPD and bronchitis are just components of airway disease". European Respiratory Journal. 28 (2): 264–267. doi:10.1183/09031936.06.00056106. PMID 16880365. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  93. ^ Diaz, P. Knoell. "Applied Therapeutics: The Clinical Use of Drugs, 9th Edition" Philadelphia: Lippincott Williams & Wilkins, 2009. Chapter 23 (Chronic Obstructive Pulmonary Disease)
  94. ^ a b NHLBI Guideline 2007, pp. 184–5
  95. ^ Ripoll, Brian C. Leutholtz, Ignacio. Exercise and disease management (2nd ed. ed.). Boca Raton: CRC Press. p. 100. ISBN 9781439827598. {{cite book}}: |edition= has extra text (help)CS1 maint: multiple names: authors list (link)
  96. ^ Tippets B Guilbert TW (2009). "Managing Asthma in Children, Part 2: Achieving and Maintaining Control". Consultant for Pediatricians. 8 (6).
  97. ^ a b c d e f NHLBI Guideline 2007, p. 213 Cite error: The named reference "NHLBI07p213" was defined multiple times with different content (see the help page).
  98. ^ a b "British Guideline on the Management of Asthma" (PDF). Scottish Intercollegiate Guidelines Network. 2008. Archived from the original (PDF) on 19 August 2008. Retrieved 2008-08-04. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  99. ^ Thomson NC, Spears M (2005). "The influence of smoking on the treatment response in patients with asthma". Curr Opin Allergy Clin Immunol. 5 (1): 57–63. doi:10.1097/00130832-200502000-00011. PMID 15643345.
  100. ^ Spears M, Cameron E, Chaudhuri R, Thomson NC (2010). "Challenges of treating asthma in people who smoke". Expert Rev Clin Immunol. 6 (2): 257–68. doi:10.1586/eci.09.85. PMID 20402388.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  101. ^ Girodet PO (2008). "What is the therapeutic response to corticosteroid in smokers with asthma?". Rev Mal Respir (in French). 25 (2): 185–92. PMID 18449080.
  102. ^ Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH (2011). "Smoking and asthma". J Am Board Fam Med. 24 (3): 313–22. doi:10.3122/jabfm.2011.03.100180. PMID 21551404.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  103. ^ PC Gøtzsche, HK Johansen (2008). Gøtzsche, Peter C (ed.). "House dust mite control measures for asthma". Cochrane Database Syst Rev (2): CD001187. doi:10.1002/14651858.CD001187.pub3. PMID 18425868.
  104. ^ Rodrigo GJ, Nannini LJ (2006). "Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials". Am J Emerg Med. 24 (2): 217–22. doi:10.1016/j.ajem.2005.10.008. PMID 16490653.
  105. ^ NHLBI Guideline 2007, p. 351
  106. ^ NHLBI Guideline 2007, p. 218
  107. ^ Cates CJ, Lasserson TJ, Jaeschke R (2009). Cates, Christopher J (ed.). "Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006922. doi:10.1002/14651858.CD006922.pub2. PMID 19588410.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  108. ^ Cates CJ, Cates MJ (2008). Cates, Christopher J (ed.). "Regular treatment with salmeterol for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006363. doi:10.1002/14651858.CD006363.pub2. PMID 18646149.
  109. ^ "FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs)". FDA. 2010. Based on the available information, FDA concludes there is an increased risk for severe exacerbation of asthma symptoms, leading to hospitalizations in pediatric and adult patients as well as death in some patients using LABAs for the treatment of asthma. The agency is requiring the REMS and class-labeling changes to improve the safe use of these products. {{cite web}}: Unknown parameter |month= ignored (help)
  110. ^ NHLBI Guideline 2007, p. 250
  111. ^ a b Rachelefsky, G (2009 Jan). "Inhaled corticosteroids and asthma control in children: assessing impairment and risk". Pediatrics. 123 (1): 353–66. doi:10.1542/peds.2007-3273. PMID 19117903. {{cite journal}}: Check date values in: |date= (help)
  112. ^ Dahl R (2006). "Systemic side effects of inhaled corticosteroids in patients with asthma". Respir Med. 100 (8): 1307–17. doi:10.1016/j.rmed.2005.11.020. PMID 16412623. {{cite journal}}: Unknown parameter |month= ignored (help)
  113. ^ a b c Rodrigo GJ, Rodrigo C, Hall JB (2004). "Acute asthma in adults: a review". Chest. 125 (3): 1081–102. doi:10.1378/chest.125.3.1081. PMID 15006973.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  114. ^ Noppen, M. (August 2002). "Magnesium Treatment for Asthma : Where Do We Stand?". Chest. 122 (2): 396–8. doi:10.1378/chest.122.2.396. PMID 12171805.
  115. ^ a b NHLBI Guideline 2007, p. 373
  116. ^ NHLBI Guideline 2007, p. 399
  117. ^ a b Castro, M (2010 Apr). "Bronchial thermoplasty: a novel technique in the treatment of severe asthma". Therapeutic advances in respiratory disease. 4 (2): 101–16. doi:10.1177/1753465810367505. PMID 20435668. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  118. ^ Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD (2001). "Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis : data from a population-based survey". Chest. 120 (5): 1461–7. doi:10.1378/chest.120.5.1461. PMID 11713120.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  119. ^ Shenfield G, Lim E, Allen H (2002). "Survey of the use of complementary medicines and therapies in children with asthma". J Paediatr Child Health. 38 (3): 252–7. doi:10.1046/j.1440-1754.2002.00770.x. PMID 12047692.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  120. ^ Kaur, B (2009). Arnold, Elizabeth (ed.). "Vitamin C supplementation for asthma". Cochrane Database Syst Rev (1): CD000993. doi:10.1002/14651858.CD000993.pub3. PMID 19160185. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |unused_data= ignored (help)
  121. ^ a b NHLBI Guideline 2007, p. 240
  122. ^ McCarney RW, Brinkhaus B, Lasserson TJ, Linde K (2004). McCarney, Robert W (ed.). "Acupuncture for chronic asthma". Cochrane Database Syst Rev (1): CD000008. doi:10.1002/14651858.CD000008.pub2. PMID 14973944.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  123. ^ Blackhall, K (2012 Sep 12). "Ionisers for chronic asthma". Cochrane database of systematic reviews (Online). 9: CD002986. PMID 22972060. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  124. ^ Hondras MA, Linde K, Jones AP (2005). Hondras, Maria A (ed.). "Manual therapy for asthma". Cochrane Database Syst Rev (2): CD001002. doi:10.1002/14651858.CD001002.pub2. PMID 15846609.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  125. ^ Sergel, Michelle J.; Cydulka, Rita K. (September 2009). "Ch. 75: Asthma". In Wolfson, Allan B.; Harwood-Nuss, Ann (eds.). Harwood-Nuss' Clinical Practice of Emergency Medicine (5th ed.). Lippincott Williams & Wilkins. pp. 432–. ISBN 978-0-7817-8943-1. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
  126. ^ Maddox L, Schwartz DA (2002). "The pathophysiology of asthma". Annu. Rev. Med. 53: 477–98. doi:10.1146/annurev.med.53.082901.103921. PMID 11818486.
  127. ^ Beckett PA, Howarth PH (2003). "Pharmacotherapy and airway remodelling in asthma?". Thorax. 58 (2): 163–74. doi:10.1136/thorax.58.2.163. PMC 1746582. PMID 12554904.
  128. ^ a b c NHLBI Guideline 2007, p. 1
  129. ^ The global burden of disease : 2004 update.. [Online-Ausg.] ed. Geneva, Switzerland: World Health Organization; 2008. ISBN 9789241563710. p. 35.
  130. ^ "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 11 November 2009. Retrieved November 11, 2009. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  131. ^ "World Health Organization Fact Sheet Fact sheet No 307: Asthma". 2009. Retrieved 2 September 2010.
  132. ^ a b Lazarus SC (2010). "Clinical practice. Emergency treatment of asthma". N. Engl. J. Med. 363 (8): 755–64. doi:10.1056/NEJMcp1003469. PMID 20818877. {{cite journal}}: Unknown parameter |month= ignored (help)
  133. ^ Braman SS (2006). "The global burden of asthma". Chest. 130 (Suppl): 4S–12S. doi:10.1378/chest.130.1_suppl.4S. PMID 16840363. {{cite journal}}: Unknown parameter |month= ignored (help)
  134. ^ a b "Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee". Lancet. 351 (9111): 1225–32. 1998. doi:10.1016/S0140-6736(97)07302-9. PMID 9643741. {{cite journal}}: Unknown parameter |month= ignored (help)
  135. ^ World Health Organization. "WHO: Asthma". Archived from the original on 15 December 2007. Retrieved 2007-12-29. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  136. ^ Anderson, HR (2007). "50 years of asthma: UK trends from 1955 to 2004". Thorax. 62 (1): 85–90. doi:10.1136/thx.2006.066407. PMC 2111282. PMID 17189533. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  137. ^ Getahun D, Demissie K, Rhoads GG (2005). "Recent trends in asthma hospitalization and mortality in the United States". Journal of asthma. 42 (5): 373–8. doi:10.1081/JAS-62995. PMID 16036412.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  138. ^ Hayden, Merrill (19 September 2009). "Asthma Guide".
  139. ^ Simpson CR, Sheikh A (2010). "Trends in the epidemiology of asthma in England: a national study of 333,294 patients". J R Soc Med. 103 (3): 98–106. doi:10.1258/jrsm.2009.090348. PMID 20200181.
  140. ^ Grant EN, Wagner R, Weiss KB (1999). "Observations on emerging patterns of asthma in our society". J Allergy Clin Immunol. 104 (2 Pt 2): S1–S9. doi:10.1016/S0091-6749(99)70268-X. PMID 10452783. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  141. ^ Anandan C, Nurmatov U, van Schayck OC, Sheikh A (2010). "Is the prevalence of asthma declining? Systematic review of epidemiological studies". Allergy. 65 (2): 152–67. doi:10.1111/j.1398-9995.2009.02244.x. PMID 19912154. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  142. ^ Murray and Nadel's textbook of respiratory medicine (5th ed. ed.). Philadelphia, PA: Saunders/Elsevier. 2010. pp. Chapter 38. ISBN 1416047107. {{cite book}}: |edition= has extra text (help); |first= missing |last= (help)
  143. ^ World Health Organization (2007). Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. pp. 15–20, 49. ISBN 978-92-4-156346-8. Archived from the original (PDF) on 18 May 2010. Retrieved 2010-05-14. {{cite book}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  144. ^ a b "Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001–2009". MMWR Morb. Mortal. Wkly. Rep. 60 (17): 547–52. 2011. PMID 21544044. {{cite journal}}: Unknown parameter |month= ignored (help)
  145. ^ Lara M, Akinbami L, Flores G,Morgenstern H (2006). "Heterogeneity of childhood asthma among Hispanic children: Puerto Rican children bear a disproportionate burden". Pediatrics. 117 (1): 43–53. doi:10.1542/peds.2004-1714. PMID 16396859.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  146. ^ Davis AM, Kreutzer R, Lipsett M, King G,Shaikh N (2006). "Asthma prevalence in Hispanic and Asian American ethnic subgroups: results from the California Healthy Kids Survey". Pediatrics. 118 (2): e363–70. doi:10.1542/peds.2005-2687. PMID 16882779.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  147. ^ Johnson DB, Oyama N, LeMarchand L,Wilkens L (2004). "Native Hawaiians mortality, morbidity, and lifestyle: comparing data from 1982, 1990, and 2000". Pac Health Dialog. 11 (2): 120–30. PMID 16281689.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  148. ^ Naqvi M, Thyne S, Choudhry S; et al. (2007). "Ethnic-specific differences in bronchodilator responsiveness among african americans, puerto ricans, and mexicans with asthma". J Asthma. 44 (8): 639–48. doi:10.1080/02770900701554441. PMID 17943575. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  149. ^ Burchard EG, Avila PC, Nazario S; et al. (2004). "Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma". Am J Respir Crit Care Med. 169 (3): 386–92. doi:10.1164/rccm.200309-1293OC. PMID 14617512. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  150. ^ Gold DR, Acevedo-Garcia D (2005). "Immigration to the United States and acculturation as risk factors for asthma and allergy". J Allergy Clin Immunol. 116 (1): 38–41. doi:10.1016/j.jaci.2005.04.033. PMID 15990770.
  151. ^ Eldeirawi KM, Persky VW (2006). "Associations of acculturation and country of birth with asthma and wheezing in Mexican American youths". J Asthma. 43 (4): 279–86. doi:10.1080/0277090060022869. PMID 16809241.
  152. ^ Bush A, Menzies-Gow A (2009). "Phenotypic differences between pediatric and adult asthma". Proc Am Thorac Soc. 6 (8): 712–9. doi:10.1513/pats.200906-046DP. PMID 20008882. {{cite journal}}: Unknown parameter |month= ignored (help)
  153. ^ Manniche L (1999). Sacred Luxuries: Fragrance, Aromatherapy, and Cosmetics in Ancient Egypt. Cornell University Press. pp. 49. ISBN 978-0-8014-3720-5.
  154. ^ a b Opolski M, Wilson I (2005). "Asthma and depression: a pragmatic review of the literature and recommendations for future research". Clin Pract Epidemol Ment Health. 1: 18. doi:10.1186/1745-0179-1-18. PMC 1253523. PMID 16185365. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)
  155. ^ Thorowgood JC (1873). "On Bronchial Asthma". British Medical Journal. 2 (673): 600. doi:10.1136/bmj.2.673.600. PMC 2294647. PMID 20747287. {{cite journal}}: Unknown parameter |month= ignored (help)
  156. ^ Gaskoin G (1872). "On the Treatment of Asthma". British Medical Journal. 1 (587): 339. doi:10.1136/bmj.1.587.339. PMC 2297349. PMID 20746575. {{cite journal}}: Unknown parameter |month= ignored (help)
  157. ^ Berkart JB (1880). "The Treatment of Asthma". British Medical Journal. 1 (1016): 917–8. doi:10.1136/bmj.1.1016.917. PMC 2240555. PMID 20749537. {{cite journal}}: Unknown parameter |month= ignored (help)
    Berkart JB (1880). "The Treatment of Asthma". British Medical Journal. 1 (1017): 960–2. doi:10.1136/bmj.1.1017.960. PMC 2240530. PMID 20749546. {{cite journal}}: Unknown parameter |month= ignored (help)
  158. ^ Bosworth FH (1886). "Hay Fever, Asthma, and Allied Affections". Transactions of the Annual Meeting of the American Climatological Association. 2: 151–70. PMC 2526599. PMID 21407325.
  159. ^ Doig RL (1905). "Epinephrin; Especially in Asthma". California State Journal of Medicine. 3 (2): 54–5. PMC 1650334. PMID 18733372. {{cite journal}}: Unknown parameter |month= ignored (help)
  160. ^ Matthews C (1910). "The use of adrenalin in acute asthma". British Medical Journal. 1 (2564): 441. doi:10.1136/bmj.1.2564.441. PMC 2330484. PMID 20764937. {{cite journal}}: Unknown parameter |month= ignored (help)
References

External links

Template:Cardiopulmonary Therapy

Template:Link FA Template:Link FA

Retrieved from "https://en.wikipedia.org/w/index.php?title=Asthma&oldid=529659414"